Human papillomavirus vaccine effectiveness study among men who have sex with men

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502224-49-00

Enrollment

730

Registered

2023-01-27

Start date

2023-02-06

Completion date

Unknown

Last updated

2023-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection, Prevention of HPV infection among healthy participants.

Brief summary

We will conduct an observational study and compare anal HPV-16/18 prevalence between vaccinated and unvaccinated MSM attending the sexual health center (SHC). We will primarily measure HPV-16 and HPV-18 DNA positivity.

Detailed description

DNA HPV16/18 DNA positivity and HPV16/18 seropositivity, HPV16/18 seropositivity 24 months post HPV vaccination

Interventions

DRUGCervarix suspension for injection in multidose container Human Papillomavirus vaccine [Types 16

DRUG18] (Recombinant

DRUGadjuvanted

DRUGadsorbed)

Eligibility

Sex/Gender

Male

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
We will conduct an observational study and compare anal HPV-16/18 prevalence between vaccinated and unvaccinated MSM attending the sexual health center (SHC). We will primarily measure HPV-16 and HPV-18 DNA positivity.	—

Secondary

Measure	Time frame
DNA HPV16/18 DNA positivity and HPV16/18 seropositivity, HPV16/18 seropositivity 24 months post HPV vaccination	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026